Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

NEJM Evidence（2023）

引用 9|浏览43

暂无评分

摘要

Combination therapy with colistin and meropenem was not superior to colistin monotherapy for the treatment of pneumonia or BSI caused by these pathogens. (Funded by the National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases protocol 10-0065; ClinicalTrials.gov number, NCT01597973.).

查看译文

关键词

colistin,combination monotherapy,carbapenem-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要